Synergetic Effects of HGF and Antibacterial Treatment

a technology which is applied in the field of synergetic effects of hgf and antibacterial treatment, can solve the problems of large problem of chronic leg wounds in elderly patients and especially in patients suffering from diabetes, difficult to heal, and patients usually suffer from combined venous and arterial insufficiency or venous insufficiency

Inactive Publication Date: 2010-06-24
NAYERI FARIBA
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]The combination of HGF and the antibiotic agent used which is relevant for the infection in question accentuates process of healing dramatically and shortens the convalescence period. HGF can be used in acute, sub-acute as well as chronic injuries caused or complicated by infectious agents.

Problems solved by technology

The presence of chronic leg wounds in elderly patients and especially in the patients suffering from diabetes is a large problem in today's health care.
These leg wounds depend on different causes such as inappropriate circulation and are therefore very difficult to heal.
These patients usually suffer from venous insufficiency or combined venous and arterial insufficiency.
At present, there is not any real satisfactory treatment.
The methods available are time consuming, difficult and costly.
Though improvement of ulcer in general, the antibacterial treatment can seldom cure the ulcers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergetic Effects of HGF and Antibacterial Treatment
  • Synergetic Effects of HGF and Antibacterial Treatment
  • Synergetic Effects of HGF and Antibacterial Treatment

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0050]HGF as a Therapeutic Predicator in Pneumonia

[0051]In a prospective study the serum values of HGF were measured in the patients with pneumonia within 24 hours (n=70), after 3 (n=70) and 5 days (n=47) and finally after 4-6 weeks (n=46). An enzyme-linked immuno-sorbent assay (ELISA) was performed. A commercially available ELISA kit (Quantikine HGF Immunoassay, R&D systems Inc., Minneapolis, USA) has been used. The patients were classified into responders and late-responders on clinical grounds and without knowledge of the HGF values.

[0052]It was found that serum HGF levels initially were high in all patients. The responders exhibited successively lower HGF levels during treatment on ward with normal values in the convalescent period (p<0.0001). In the late-responders the levels remained unchanged or increased and did not decrease (ANOVA; n=70; p<0.0005) until the appropriate treatment was initiated. The HGF levels followed sensitively the antibacterial choice.

[0053]Measuring HGF ...

example 2

[0054]Hepatocyte Growth Factor Accelerates Healing in Chronic Leg Ulcers

[0055]A gel containing HGF and heparin was prepared as follows:

[0056]Preparation 1: Sterile PBS Solution Containing polysorbat 80

Potassium chloride0.20gMonopotassium phosphate0.20gDisodium dihydrogen phosphate1.40gSodium chloride8.00gPolysorbat 8050mgWater to1000ml

[0057]Preparation 1 can be prepared in advance and be dispensed in 100 ml injection bottles.

[0058]Preparation 2: Sterile PBS Gel

Hypromellos20.0gPreparation 1to 1000ml

[0059]Preparation 1 and 2 can be prepared in advance and be dispensed in 100 ml injection bottles. The following preparations 3 to 5 are prepared just before the usage of the same.

[0060]Preparation 3: Diluent Fluid

Albumin (200 mg / ml, Pharmacia & Upjohn) 25.0 mlHeparin (25.000 IE / ml, Lövens)  0.8 mlPreparation 1 to1000 ml

[0061]Preparation 4: HGF Solution

Hepatocyte growth factor (HGF)10μgPreparation 3 to100mlgiving 100 ng HGF per ml

[0062]In order to prepare HGF preparations, recombinant huma...

example 3

[0070]Increased Serum Levels of HGF in the Patients With Acute Infectious Diseases.

[0071]In a prospective study we have measured the serum HGF levels from patients with different infectious diseases and from healthy adults and elderly. An enzyme-linked immuno-sorbent assay (ELISA) method was used. Six clinical groups were identified (n=10 in each group): gastroenteritis, skin and soft tissue infection, urinary tract infection, septicemia, pneumonia, and chronic hepatitis C. Seventy-five healthy persons served as a control group. We found higher levels of HGF in the sera from patients with acute infectious diseases (Group 1-5) compared to the healthy population as well as compared to the patients with chronic hepatitis C (p<0.0001). CRP and HGF were highly correlated (r=0.65). We conclude that HGF rises in serum from patients with acute infectious diseases but possibly not in chronic infections.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of treating an infection and / or an injury caused or complicated by an infection in a mammal, comprising providing an antibiotic or fungicide and either HGF or a polypeptide exhibiting HGF activity to said mammal. In one embodiment, the injury is not a chronic skin ulcer.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a composition and a method for treatment of injury caused or complicated by infections such as pneumonia, injuries in the respiratory organs caused by burns and / or infections and infected chronic leg ulcers in the patients suffering from diabetes, venous or combined venous / arterial insufficiency, wherein a therapeutically active amount of HGF (hepatocyte growth factor) and at least antibiotic agent to which the infection in question respond are administered to a mammal suffering from such injury. The present invention also relates to analysis of excrement with regard to HGF, as well as a kit for carrying out the analysis for the diagnosis of certain illness conditions where HGF has turned out to be an important factor.THE BACKGROUND OF THE INVENTION[0002]Hepatocyte growth factor, (HGF), is a protein expressed in the mesenchymal cells such as lung macrophages and fibroblasts, kupffer cells in the liver and leukocytes. HGF i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/18A61P33/08A61P31/02A61P31/00A61P31/06G01N33/74
CPCA61K38/1833G01N33/74G01N2333/4753A61K2300/00A61P31/00A61P31/02A61P31/04A61P31/06A61P33/08
Inventor NAYERI, FARIBA
Owner NAYERI FARIBA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap